Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Leases (2016 - 2018)

Historic Capital Leases for ImmunityBio (IBRX) over the last 3 years, with Q4 2018 value amounting to $5.9 million.

  • ImmunityBio's Capital Leases rose 24147.04% to $5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.9 million, marking a year-over-year increase of 24147.04%. This contributed to the annual value of $5.9 million for FY2018, which is 24147.04% up from last year.
  • According to the latest figures from Q4 2018, ImmunityBio's Capital Leases is $5.9 million, which was up 24147.04% from $6.1 million recorded in Q3 2018.
  • In the past 5 years, ImmunityBio's Capital Leases registered a high of $6.3 million during Q2 2018, and its lowest value of $1.7 million during Q1 2018.
  • In the last 3 years, ImmunityBio's Capital Leases had a median value of $2.0 million in 2016 and averaged $3.2 million.
  • In the last 5 years, ImmunityBio's Capital Leases crashed by 2410.04% in 2017 and then surged by 24147.04% in 2018.
  • Quarter analysis of 3 years shows ImmunityBio's Capital Leases stood at $2.0 million in 2016, then dropped by 14.02% to $1.7 million in 2017, then skyrocketed by 241.47% to $5.9 million in 2018.
  • Its Capital Leases stands at $5.9 million for Q4 2018, versus $6.1 million for Q3 2018 and $6.3 million for Q2 2018.